:ry and P e d i a t r i c s , Torrance, CA B r a i n and somatic grbwth are retarded by both experimental hy per-and hypothyroidism i n the developing r a t . Because o f i ncreasing use o f t h y r o i d rep7acement therapy i n the human neonate we studied the e f f e c t s o f abnormal t h y r o i d states on rGH during the neonatal period.
L i t t e r s o f newborn r a t pups were i n j e c t e d d a i l y from ages 0-1 days w i t h thyroxine (T4). 0.4 ug/gram o f body weight, w h i l e l i ttennate c o n t r o l s were i n j e c t e d d a i l y w i t h s a l i n e . Other l i t t e r s were rendered hypothyroid by i n j e c t i o n o f the mothers w i t h 50 mg p r o p y l t h i o u r a c i l (PTU) d a i l y from 10 days g e s t a t i o n v i a i n t r ag a s t r i c gavage. Controls received an equal volume o f s a l i n e .
I n both experimental groups, the developmental curve f o r rGH i n c o n t r o l s as measured by radioinunoassay f e l l from 120 ngjml on day one t o 10 nglml on day 19. Both thyroxine and PTU treatel pups showed a consistent depression i n rGH l e v e l s a t each age o f e a r l y development. The maximum d e f i c i t i n T4 animals was 6% o f c o n t r o l a t day 18, and i n PTU animals, was 14% o f c o n t r o l a t day 15. I n d i v i d u a l data p o i n t s f o r t r e a t e d and c o n t r o l animals were l o g transformed, f o l l o w i n g which the developmental p r o f i l e s wpre analyzed by a one way analysis o f covariance. Both hyper-and lypothyroid pups showed a s t a t i s t i c a l l y s i g n i f i c a c t d e f i c i e n c y o GH throughout e a r l y development. The e a r l y suppression i n both onditions suggests the necessity f o r c a r e f u l t i t r a t i o n o f thyo i d replacement therapy i n human congenital hypothyroidism.
I
Among 15 infants with CH, 6 were identified in our screening program with an elevated cord TSH ( > 100 ~U/ml) and low Tq (< 5 pgldl), and placed on thyroid hormone therapy within the first 1
Univ. of Pittsburgh, of Pittsburgh, Pittsburgq month of life. Within 4 weeks of therapy their serum TSH was suppressed below 12 pU/ml either by treatment with Tq alone or T and Tq combination therapy. An additional 9 infants not involve in a screening program were identified by clinical symptoms and referred for evaluation. Three infants were initially treated with 25 pg qd of T3, and sermn TSH was < 12 pU/ml in all within weeks. However, among 5 of 6 infants treated with Tq alone, the TSH did not suppress below 12 pU/ml until >/ 3 months of therapy.
During therapy in the 7 infants treated with T4 alone, serial reverse T (rTg) determinations revealed peak concentrations (10 + 13.8 ngjdl, mean 2 SEM) simultaneous with the initial suppression of TSH to normal and significantly greater than the rT3 levels just prior to suppression of TSH (66.7 2 15 ngldl, p<.OO1 by paired t test) and following TSH suppression (83.8 5 16 ng/dl ><.05).
In summary, 1) Tq alone is adequate therapy for CH iden tified early by screening programs, but is associated with delay ~d TSH suppression in infants diagnosed on the basis of clinic41 symptomatology alone. 2) The peak rT3 levels associated with the .nitial TSH suppression suggest an increase in the monodeiodina-:ion of Tq to rT3, or decreased clearance of rT3 which may indi-:ate the development of intracellular euthyroidism.
HYPOGONADOTROPIC HYPOGONADISM (HHG) IN ACUTE INTERMI7
TENT PORPHYRIA (AIP), Nezam Radfar, Thomas P. Foley, Jr., Arthur K. Katoh, Robert S. Chabon, Univ. Pittsbu Ped., Mercy Hospital, Depts. of Ped. and Radiology Pittsburgh, PA HHG in AIP has not been reported. A 20 yr. old male with AIP and inappropriate secretion of ADH was hyposmic, tall (178 cm), eunuchoid (U/L, 0.84), had a high-pitched voice, absent facial hair and Tanner 2-3 pubic hair. His testes were small (R, 8 ml; L, 10 ml). Karyotype was XY. Basal serum FSH, 5.5 mIU/ml; LH, 5.6 mIU/ml and T, 54 ng/dl were all low and PRL was normal. Meal nocturnal LH (6.5 2 0.2 (SE) mI~/ml) was low and showed no perio. dic pulses. Mean nocturnal T (156 + 13 ng/dl) was also low, wit1 minimal fluctuations between 2200 h and 0300 h; however, between 0300 h and 0800 h. two peaks of T occurred simultaneously with those of cortisol. The responses of LH to LHRH and TSH and PRL to TRH were normal. Nocturnal GH secretion was characterized by 3 peaks. Basal GH was normal and increased to 16 ng/ml during AITT and remained above 10 ng/ml between 60 and 150 minutes. Basal T, 252 ng/dl, increased to 2049 ng/dl after 4 days of in hCG (5000 unitsld) . Basal 24 h urine amino levulinic acid (ALA), 18 mg and porphobilinogen (PBG), 68 mg, respectively, were high and did not change after 4 days of hCG (ALA, 25 mg/d; PBG, 51 mg/d).
Three attacks of AIP occurred during 8 months prior to T therapy, but none occurred during 7 months of hCG or T therapy. Conclusions: 1) Hypothalamic dysfunction in AIP may cause HHG 2) ~c G and T do not alter ALA and PBG excretion and Protect these patients from re~eated attacks. Measurement of serum and urine C-peptide (CPR) have been used to demonstrate residual insulin producing capacity in diabetes. The duration and dynamics of residual 6-cell function have not been thoroughly investigated. Sequential measurement of serum and urine CPR were made during and after therapy for ketoacidosis in a 15 year old boy with JODM of 10 months duration. Serum CPR ranged from 0.3-0.6 ng/ml, approaching the lowest levels detectable by RIA. Urine C-peptide excretion increased over the 5 days of observation.
C --85 Urinary clearance and fractional excretion (CC-peptide/Ccreat ) of C-peptide also increased 6-10 fold.
Despite low serum CPR, these data are compatible with increased endogenous insulin production during therapy for ketoacidosis. Changes in renal blood flow or tubular disposition of --peptide may have contributed to the progressive increase in urine C-peptide excretion.
iXX (THDOC), free DOC and 18-OH-DOC, measured by specific radioimmunoassay, were similar in 7 children with essential hypertension and 4 patients with dexamethasone-suppressible hyperaldoste ronism when compared with 5 normotensive controls (plasma DOC: 16.3?3.0 ng/dl, urinary excretion (ug/m2/24h) of THWC: 23.5f5.0 free DOC: 0.1t0.01, free 18-OH-DOC: 0.8f0.2).
There was no corelation between DOC and 18-OH-DOC levels and plasma renin activ ty, severity or type of hypertension. During a continuous 5-da CTH infusion (40 U/24h) urinary 18-OH-DOC increased 20-50 fold n all groups. Plasma DOC concentration and urinary THECC excre ion increased 20 fold, and urinary free ECC rose 20-50 fold in he control group and in the children with essential hypertenion. The highest increase of THDOC (50 fold The testosterone (T) secretion of collagenase-dispersed rat interstitial cells exposed to gonadotropin provides a highly sensitive in vitro bioassay (RICT) for LH (Dufau 5 al, JCEM 39: 610, 1 9 7 4 ) :
T h e e r u m levels of biologically active (B) LH and the relationship to immunoreactive (I) LH have been studied in 12 prepubertal (PRE) (age 2-17, T=9.0 &dl) and 12 pubertal (PUB) (age 10-16, T=164) normal males. Mean B-LH levels in PRE ( < lmIUlml, IRP-2-hMG) are significantly (p <.001) lower than in PUB (13.8t2.4 (R~sE). B-LH was undetectable in all PRE and not separable by Tanner stages in PUB. I-LH levels, measured by double-antibody RIA, in PRE (3.6t1.0) are also lower (p < .01) than in PUB (9.3t1.5).
BII ratios in PRE (<0.6) are lower than in PUB (2.1k0.7).
The B/I ratio in PRE is lower than in normal adult males (2.5'0.1) and closer to the levels reported in normal premenopausal women (1.2t0.1). The B/I ratio in PUB does not differ from that in adult males. In conclusion: (1) The RICT bioassay method for quantitating serum LH is applicable to studies in childhood; (2) RIA measurements of LH apparently overestimate true bioactive concentrations in subjects with minimal pituitary LH secretion; (3) The similarity of B/I ratio in PRE males to adult premenopausal women and in PUB to adult males suggests that sex steroids may modulate the biologic quality, as well as quantity, of pituitary LH secretion.
